MedTrace Logo

Effect of Nalbuphine Versus Fentanyl on Hemdoynamic Effects of Laryngoscopy

NCT07435337 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2026-02-27

No results posted yet for this study

Summary

Participants will undergo routine pre-operative evaluation. An intravenous line will be placed in the recovery area. On arrival in the operating room, standard monitoring (blood pressure, heart rate, oxygen saturation, ECG, breathing monitor, and temperature) will be applied. A central venous catheter and an arterial line will be inserted under local anesthesia using sterile technique.

Before anesthesia induction, patients will receive premedication including midazolam and an opioid pain-relief injection given slowly through the vein. General anesthesia will then be induced with etomidate. After adequate sedation, a muscle relaxant (atracurium) will be administered, and the patient will be ventilated with 100% oxygen using a face mask. The breathing tube will then be inserted and correct placement confirmed.

During surgery, anesthesia will be maintained with oxygen, sevoflurane gas, and a continuous atracurium infusion. Hemodynamic parameters such as heart rate and blood pressure will be monitored throughout the peri-intubation and intraoperative period.

Conditions

  • Laryngoscopy
  • Hemodynamic Changes

Interventions

DRUG

Nalbuphine

IV Nalbuphine at dose of 0.2 mg/kg will be given 5 minutes before induction of anesthesia

DRUG

Fentanyl

3 Microgram per kilogram body weight IV Fentanyl will be given 5 minutes before induction of anesthesia

Sponsors & Collaborators

  • Rawalpindi Institute of Cardiology

    lead OTHER

Principal Investigators

  • Qudsia Qureshi, MBBS · Head of Department of Anesthesia

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-21
Primary Completion
2026-05-21
Completion
2026-05-21

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07435337 on ClinicalTrials.gov